本所及本所律师依据法律法规及本法律意见出具日以前已经发生或者存在的事实, 严 格履行了法定职责, 遵循了勤勉尽责和诚实信用原则, 进行了充分的核查验证, 保证本法律 意见所认定的事实真实、准确、完整, 所发表的结论性意见合法、准确, 不存在虚假记载、 误导性陈述或者重大遗漏, 并承担相应法律责任。 在此基础上, 本所律师出具法律意见如下: 24SH7200110/PC/pz/cm/D5 上海市通力律师事务所 关于湖北省宏源药业科技股份有限公司 2025 年第二次临时股东大会的法律意见书 致: 湖北省宏源药业科技股份有限公司 上海市通力律师事务所(以下简称"本所")接受湖北省宏源药业科技股份有限公司(以 下简称"公司")的委托, 指派本所纪宇轩律师、赵伯晓律师(以下简称"本所律师")根据 《中华人民共和国公司法》《中华人民共和国证券法》等法律法规和规范性文件(以下统称"法 律法规")及《湖北省宏源药业科技股份有限公司章程》(以下简称"公司章程")的规定就 公司 2025 年第二次临时股东大会(以下简称"本次股东大会")相关事宜出具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予 ...

证券代码：301246 证券简称：宏源药业 公告编号：2025-041 湖北省宏源药业科技股份有限公司 买卖公司股票情况的自查报告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 湖北省宏源药业科技股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日召开了第四届董事会第十一次会议、第四届监事会第十次会议，审议通过了《关 于<2025 年限制性股票激励计划（草案）>及其摘要的议案》等相关议案。具体 内容详见公司于 2025 年 8 月 28 日在中国证券监督管理委员会（以下简称"中国 证监会"）指定的创业板信息披露网站巨潮资讯网（www.cninfo.com.cn）上披露 了《2025 年限制性股票激励计划（草案）》及其摘要、《2025 年限制性股票激 励计划实施考核管理办法》等相关文件。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《深 圳证券交易所创业板上市公司自律监管指南第 1 号——业务办理》（以下简称 "《自律监管指南第 1 号》"）等有关法律法规及规范性文件的相关规定，公司 通过向中国证券登记结算有限责任公司深圳 ...

证券日报网讯宏源药业（301246）9月12日在互动平台回答投资者提问时表示，目前公司已完成公斤级 硫化物电解质前驱体及电解质样品制备，并进行测试优化工作。公司的产品生产情况及规划请关注公司 的信息披露。 ...

证券代码：301246 证券简称：宏源药业 公告编号：2025-039 董事会薪酬与考核委员会关于 2025 年限制性股票 激励计划首次授予激励对象名单的公示情况说明 湖北省宏源药业科技股份有限公司 及核查意见 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 湖北省宏源药业科技股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日召开了第四届董事会第十一次会议、第四届监事会第十次会议，审议通过了《关 于<2025 年限制性股票激励计划（草案）>及其摘要的议案》等相关议案。根据 《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证 券法》《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《深圳 证券交易所创业板股票上市规则》（以下简称"《上市规则》"）、《深圳证券 交易所创业板上市公司自律监管指南第 1 号——业务办理》（以下简称"《自律 监管指南第 1 号》"）等相关法律法规及《湖北省宏源药业科技股份有限公司章 程》（以下简称"《公司章程》"）的有关规定，公司对 2025 年限制性股票激 励计划（以下简称"本次激励计 ...

证券代码：301246 证券简称：宏源药业 公告编号：2025-038 湖北省宏源药业科技股份有限公司 监事会关于 2025 年限制性股票激励计划首次授予 激励对象名单的公示情况说明及核查意见 本公司及监事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 湖北省宏源药业科技股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日召开了第四届董事会第十一次会议、第四届监事会第十次会议，审议通过了《关 于<2025 年限制性股票激励计划（草案）>及其摘要的议案》等相关议案。根据 《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证 券法》《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《深圳 证券交易所创业板股票上市规则》（以下简称"《上市规则》"）、《深圳证券 交易所创业板上市公司自律监管指南第 1 号——业务办理》（以下简称"《自律 监管指南第 1 号》"）等相关法律法规及《湖北省宏源药业科技股份有限公司章 程》（以下简称"《公司章程》"）的有关规定，公司对 2025 年限制性股票激 励计划（以下简称"本次激励计划"）拟首次授予激 ...

格隆汇9月10日丨宏源药业(301246.SZ)在互动平台表示，目前公司已完成公斤级硫化物电解质前驱体及 电解质样品制备，就固态电解质进行测试优化工作。 ...

Core Insights - Hongyuan Pharmaceutical experienced a decline of 1.51% on September 3, with a trading volume of 45.42 million yuan [1] - The company reported a net financing outflow of 3.80 million yuan on the same day, with a total financing and securities balance of 107 million yuan [1] - As of June 30, the company recorded a revenue of 883 million yuan for the first half of 2025, a year-on-year decrease of 1.73%, and a net profit attributable to shareholders of -5.81 million yuan, down 116.23% year-on-year [2] Financing and Trading Activity - On September 3, Hongyuan Pharmaceutical had a financing buy-in of 3.24 million yuan, with a current financing balance of 107 million yuan, representing 3.59% of its market capitalization [1] - The company's financing balance is above the 80th percentile of the past year, indicating a high level of financing activity [1] - The short-selling activity on the same day included 100 shares sold, with a total value of 1,431 yuan, and a short-selling balance of 21,180 yuan, which is below the 30th percentile of the past year [1] Shareholder and Dividend Information - As of June 30, the number of shareholders increased by 3.27% to 31,000, while the average number of circulating shares per person decreased by 4.20% to 5,155 shares [2] - Since its A-share listing, Hongyuan Pharmaceutical has distributed a total of 71.81 million yuan in dividends [3] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is a new entrant, holding 1.30 million shares, while Southern CSI 1000 ETF has exited the list [3]

Group 1 - Tianqi Materials reported a revenue of 7.03 billion yuan for the first half of 2025, a year-on-year increase of 28.97% [2][3] - The net profit attributable to shareholders was 268 million yuan, up 12.79% year-on-year, while the net profit excluding non-recurring items was 235 million yuan, reflecting a growth of 26.01% [2][3] - Basic earnings per share increased to 0.14 yuan, a rise of 16.67% compared to the previous year [3] Group 2 - New Zobang achieved a revenue of 4.25 billion yuan, marking an 18.58% increase year-on-year, with a net profit of 484 million yuan, up 16.36% [5][6] - The net profit excluding non-recurring items was 466 million yuan, showing an 8.16% increase [5][6] - Basic earnings per share rose to 0.64 yuan, a 16.36% increase from the previous year [6] Group 3 - Ruida New Materials reported a revenue of 975 million yuan, a decline of 7.36% year-on-year, with a net profit of 82 million yuan, down 24.19% [7][8] - The net profit excluding non-recurring items was 79 million yuan, reflecting a decrease of 27.57% [7][8] - The company experienced a negative cash flow from operating activities of 80 million yuan [8] Group 4 - Yongtai Technology reported a revenue of 2.61 billion yuan, a year-on-year increase of 21.97%, with a net profit of 59 million yuan, up 56.17% [10][11] - The net profit excluding non-recurring items was 23 million yuan, down 15.08% [10][11] - Basic earnings per share increased to 0.06 yuan, a 50% rise compared to the previous year [11] Group 5 - Shida Shenghua reported a revenue of 3.01 billion yuan, a year-on-year increase of 14.87%, but a net loss of 56 million yuan, a decline of 248.03% [13][14] - The net loss excluding non-recurring items was 57 million yuan, down 282.11% [13][14] - The company reported a positive cash flow from operating activities of 90 million yuan [14] Group 6 - Duofluor reported a revenue of 4.33 billion yuan, a decline of 6.65% year-on-year, with a net profit of 51 million yuan, down 16.55% [15][16] - The net profit excluding non-recurring items was a loss of 4.81 million yuan, reflecting a decrease of 179.71% [15][16] - Basic earnings per share decreased to 0.0441 yuan, down 15.19% [16] Group 7 - Tianji Co. reported a revenue of 1.07 billion yuan, a year-on-year increase of 19.16%, but a net loss of 52 million yuan, an improvement of 59% compared to the previous year [18][19] - The net loss excluding non-recurring items was 56 million yuan, down 56.04% [18][19] - The company reported a negative cash flow from operating activities of 131 million yuan [19] Group 8 - Huayu Pharmaceutical reported a revenue of 882 million yuan, a decline of 1.73% year-on-year, with a net loss of 5.81 million yuan, a decline of 116.23% [21][22] - The net loss excluding non-recurring items was 21.59 million yuan, down 247.06% [21][22] - The company reported a negative cash flow from operating activities of 169 million yuan [22] Group 9 - Haike New Source reported a revenue of 2.32 billion yuan, a year-on-year increase of 27.92%, but a net loss of 42 million yuan, an improvement of 61.21% [23][24] - The net loss excluding non-recurring items was 49 million yuan, down 56.57% [23][24] - The company reported a negative cash flow from operating activities of 248 million yuan [24] Group 10 - Hualu Hengsheng reported a revenue of 15.76 billion yuan, a decline of 7.14% year-on-year, with a net profit of 1.57 billion yuan, down 29.47% [26][27] - The net profit excluding non-recurring items was 1.56 billion yuan, reflecting a decrease of 30.29% [26][27] - Basic earnings per share decreased to 0.739 yuan, down 29.48% [27] Group 11 - Huasheng Lithium reported a revenue of 349 million yuan, a year-on-year increase of 72.02%, but a net loss of 72 million yuan [29] - The net profit excluding non-recurring items was a loss of 78 million yuan [29] - The company reported a negative cash flow from operating activities of 183 million yuan [29] Group 12 - Fuxiang Pharmaceutical reported a revenue of 514 million yuan, a decline of 24.58% year-on-year, with a net loss of 6.91 million yuan, an increase of 69.23% [31][32] - The net loss excluding non-recurring items was 32 million yuan, reflecting a decrease of 34.91% [31][32] - The company reported a negative cash flow from operating activities of 10 million yuan [32] Group 13 - Furui Co. reported a revenue of 2.59 billion yuan, a decline of 3.03% year-on-year, but a net profit of 246 million yuan, an increase of 10.92% [34][35] - The net profit excluding non-recurring items was 250 million yuan, reflecting a growth of 15.71% [34][35] - The company reported a positive cash flow from operating activities of 447 million yuan [35] Group 14 - The overall performance of companies in the electrolyte and raw material sector has been poor, with most companies reporting unsatisfactory financial results [36] - Except for Tianqi and New Zobang, other companies in the electrolyte sector have shown average performance [36] - Companies in the lithium hexafluorophosphate sector have reported significant losses, with net profits declining across the board [36]

Group 1 - The core point of the article highlights that Hongyuan Pharmaceutical (301246.SZ) is currently experiencing a decline in stock price, closing at 14.63 yuan with a drop of 3.81%, resulting in a total market capitalization of 5.852 billion yuan [1] - The company went public on March 20, 2023, on the Shenzhen Stock Exchange's ChiNext board, issuing 47.2572 million shares at an initial price of 50.00 yuan per share [1] - On its first trading day, the stock reached a peak price of 45 yuan but has since experienced a downward trend [1] Group 2 - Hongyuan Pharmaceutical raised a total of 236.286 million yuan through its initial public offering, with a net amount of 219.58437 million yuan after deducting issuance costs, which exceeded the original plan by 154.51137 million yuan [1] - The company had initially planned to raise 65.073 million yuan for projects including a research center, multifunctional testing workshop, antiviral raw materials and intermediates project, and a high-end formulation workshop with an annual production capacity of 2.5 billion tablets [1] - The total issuance costs amounted to 16.70163 million yuan, with underwriting and sponsorship fees accounting for 13.93196 million yuan [1]

Core Viewpoint - The legal opinion issued by Shanghai Tongli Law Firm confirms that Hubei Hongyuan Pharmaceutical Technology Co., Ltd. is legally qualified to implement its 2025 Restricted Stock Incentive Plan, having complied with relevant laws and regulations [4][19]. Group 1: Implementation Conditions - Hubei Hongyuan holds a valid business license issued by the Huanggang Market Supervision Administration, confirming its legal existence as a joint-stock limited company [4]. - The company has received approval from the China Securities Regulatory Commission for its initial public offering, issuing 47.2572 million shares at a par value of 1 RMB per share, which began trading on March 20, 2023 [5]. - The company has no disqualifying conditions under the regulations that would prevent it from implementing the stock incentive plan [6]. Group 2: Legal Compliance of the Incentive Plan - The draft of the 2025 Restricted Stock Incentive Plan was approved by the company's board of directors, outlining its objectives, management structure, and eligibility criteria for participants [6][7]. - The plan includes detailed provisions on the number of shares to be granted, the criteria for vesting, and the rights and obligations of both the company and the incentive recipients [7][8]. Group 3: Procedures for Implementation - The company has followed necessary procedures, including the review and approval of the incentive plan by the board and the supervisory committee, and must disclose relevant information to shareholders [10][11]. - The plan requires approval from at least two-thirds of the voting rights held by non-related shareholders at the shareholders' meeting [19]. Group 4: Impact on Company and Shareholders - The incentive plan aims to enhance corporate governance, attract and retain key personnel, and align the interests of shareholders and management, thereby promoting sustainable development [19]. - The plan will not involve financial assistance to the incentive recipients, ensuring compliance with relevant regulations [19][16]. Group 5: Conclusion - The legal opinion concludes that the draft incentive plan complies with the Company Law, Securities Law, and other relevant regulations, and has met the necessary procedural and disclosure requirements [19][20].